RD
Therapeutic Areas
Rectify Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dual-targeted ABCB4/BSEP PFM | Primary Sclerosing Cholangitis (PSC) (Lead), with expansion to PBC, LPAC, GACC, PFICs, NASH | Pre-clinical |
| ABCC6-targeted PFM | Chronic Kidney Disease (CKD), Aortic Valve Stenosis (AVS) | Pre-clinical |
| Dual-targeted ABCD1/ABCD2 PFM | Adrenomyeloneuropathy (AMN), Adrenoleukodystrophy (ALD) | Pre-clinical |
| Multiple Target PFMs | Diseases caused by membrane protein dysfunction (ABC, SLC, GPCR, Ion Channel) | Discovery |
Leadership Team at Rectify Pharmaceuticals
PB
Pol Boudes, M.D.
Chief Medical Officer
RH
Robert Hughes, Ph.D.
Chief Scientific Officer
JM
John Miller, Ph.D.
Vice President, Head of Biology
NF
Nathan Fuller, Ph.D.
Vice President, Chemistry
SL
Scott Lewis, MBA
Head of Strategic Planning